TNF Alpha Inhibitors Global Market Report 2024

The tnf alpha inhibitors market size has grown marginally in recent years. It will grow from $43.09 billion in 2023 to $43.57 billion in 2024 at a compound annual growth rate (CAGR) of 1.1%. The expansion witnessed in the historical period can be ascribed to the integration of healthcare systems, the adoption of physicians and prescriptions, increasing patient demand and awareness, advancements in biotechnology, and the broadening of indications.

The tnf alpha inhibitors market size is expected to see steady growth in the next few years. It will grow to $47.54 billion in 2028 at a compound annual growth rate (CAGR) of 2.2%. The anticipated growth in the forecast period is linked to precision drug delivery, a patient-centric focus, the evolution of immunotherapy, market expansion strategies, and a personalized medicine approach. Key trends expected during this period encompass the utilization of real-world evidence, the adoption of combination therapies, market entry strategies, the broadening of therapeutic applications, and increased competition in biosimilars.

The growth of the TNF alpha inhibitor market is driven by the increasing prevalence of inflammatory diseases such as inflammatory bowel disease and psoriasis. TNF alpha inhibitors find widespread use in gastroenterology, dermatology, and rheumatology for treating various immune-mediated inflammatory conditions. Globally, the prevalence of inflammatory bowel disease (IBD) ranges from 0.5-24.5 cases of ulcerative colitis per 100,000 person-years and 0.1-16 cases of Crohn's disease per 100,000 person-years. The overall IBD prevalence stands at 396 cases per 100,000 people annually. Consequently, the rising incidence of inflammatory diseases contributes to a growing demand for TNF alpha inhibitors, fostering market expansion.

The TNF alpha inhibitor market is expected to witness growth due to an increasing geriatric population. The elderly, aged 65 and above, are more prone to autoimmune disorders and heightened inflammatory activity, making TNF-alpha inhibitors effective in reducing inflammation and atherosclerosis in this demographic. For instance, the World Health Organization projected that by October 2021, there would be 1.4 billion people aged 60 and above, compared to 1 billion in 2020. The global population aged 60 or older is anticipated to double to 2.1 billion by 2050, with the number of individuals aged 80 or older tripling to reach 426 million. Hence, the expanding geriatric population is a significant driver for the TNF alpha inhibitors market.

The growth of the TNF alpha inhibitor market is expected to face limitations due to the adverse side effects experienced by patients. Clinical trials and post-marketing surveillance have identified multiple adverse effects of TNF alpha inhibition, including injection site reactions, neutropenia, infusion reactions, and infections. According to the U.S. Food and Drug Administration (FDA), TNF alpha inhibitors can lead to severe infections in individuals with compromised immune systems, making them susceptible to bacterial, mycobacterial, fungal, or viral infections. Such infections may manifest as tuberculosis, histoplasmosis, candidiasis, blastomycosis, and hepatitis B. Consequently, the presence of these side effects prompts patients to seek alternatives such as non-TNF biologics, thereby impeding the growth of the TNF alpha inhibitors market.

Companies in the TNF alpha inhibitor market are directing their efforts towards research and development. This focus on R&D enables market players to assess and embrace high-quality research proposals from global sources, aiming to deliver biologically and clinically superior performance that ensures a more comfortable patient experience and faster recovery times. A case in point is MyMD Pharmaceuticals, Inc., a US-based clinical stage pharmaceutical company dedicated to extending healthy lifespans. In February 2022, the company disclosed Phase 1 clinical trial data indicating MYMD-1's capacity to reduce tumor necrosis factor-alpha (TNF-α), the molecules considered the root cause of aging, in the blood of healthy human subjects. MYMD-1 has demonstrated efficacy in pre-clinical studies by regulating the immune system as a selective inhibitor of TNF-α, a driver of chronic inflammation.

Major players in the TNF alpha inhibitor market are also actively engaging in strategic collaborations to expand their product portfolios and make TNF-blockers more widely accessible to patients. Product distribution, in this context, involves dispersing products such as TNF-alpha inhibitors throughout the market for purchase. For instance, in June 2023, Mark Cuban Cost Plus Drug Company, a US-based pharmaceutical company, collaborated with Coherus BioSciences Inc., a US-based biopharmaceutical company. The partnership aimed to provide Mark Cuban Cost Plus Drug Company customers with YUSIMRY (adalimumab-aqvh), a biosimilar of HUMIRA (adalimumab injection), a TNF blocker approved for various conditions. This collaboration is part of Coherus' biosimilar strategy, leveraging its manufacturing and supply chain management capabilities to produce safe and efficient biosimilars with a dependable supply.

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics PLC for $27.8 billion. This acquisition aligns with Amgen's core business objective of offering groundbreaking medications that significantly improve the lives of patients with critical diseases. Horizon Therapeutics PLC, a US-based biopharmaceutical company, is involved in developing and marketing TNF inhibitors for treating rheumatoid arthritis (RA).

Major companies operating in the tnf alpha inhibitors market report are HanAll Biopharma Co.Ltd., Pfizer Inc., Johnson & Johnson, Janssen Biotech lnc., Merck & co. Inc., AbbVie Inc., Novartis International AG, Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Boehringer Ingelheim International GmbH, Amgen Inc., Celgene Corporation, LEO Pharma A/S, Biogen Inc., Sandoz International GmbH, Cadila Healthcare Limited, Bionovis SA, UCB S.A, Intas Pharmaceuticals Ltd., Samsung Bioepis Co.Ltd., Celltrion Healthcare Co. Ltd., LG Life Sciences Ltd., MedImmune LLC, AryoGen Pharmed Co.Ltd., Ablynx NV, Reliance Life Sciences Pvt. Ltd., CASI Pharmaceuticals Inc., Momenta Pharmaceuticals lnc., EPIRUS Biopharmaceuticals lnc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, The Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Gilead Sciences Inc., Ipsen S.A., Kyowa Kirin Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Mylan N.V., Regeneron Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Hospira Inc., Apotex Inc. North America was the largest region in the TNF alpha inhibitors market in 2023. The regions covered in the tnf alpha inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The primary drugs in the TNF alpha inhibitors market include Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol), and Simponi (golimumab). Remicade is prescribed for individuals with moderately to severely active Crohn's disease who have not responded to alternative treatments. These medications can be administered through various routes, including oral, subcutaneous, intravenous, among others, and are used to treat a range of conditions such as inflammatory bowel disease, psoriatic arthritis, ulcerative colitis (UC), rheumatoid arthritis, ankylosing spondylitis, and more.

The TNF alpha inhibitors market research report is one of a series of new reports that provides TNF alpha inhibitors market statistics, including global market size, regional shares, competitors with a TNF alpha inhibitors market share, detailed TNF alpha inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the TNF alpha inhibitors industry. This TNF alpha inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The countries covered in the tnf alpha inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The TNF alpha inhibitors market consists of sales of infliximab, adalimumab, etanercept, golimumab, and certolizumab. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.